What AVINza Treats: Main Uses and Benefits

Relief from Severe and Persistent Pain Symptoms

The medication is applied in addressing symptoms related to physical discomfort that may require long-term symptomatic support. It is relevant when supportive symptom management is appropriate in contexts where existing measures have not fully eased discomfort. It is commonly used across conditions presenting with systemic or localized discomfort, such as persistent chronic pain, where the patient requires assistance in maintaining functional stability.

Providing Stable, Continuous Comfort

The therapeutic approach is relevant for easing symptoms that require a steady, continuous level of symptomatic support. This helps address symptom clusters that are present around the clock and create noticeable physiological strain. Continuous symptomatic support may assist with maintaining functional stability and contributes to easing the overall symptom load.

“It is applied across therapeutic domains where additional symptomatic support is needed, assisting with the overall burden of distressing symptoms.”

Quick Fact: Relief for Symptoms of Increased Discomfort

Indications Summary

It is applied in addressing symptoms related to physical discomfort that may require sustained, around-the-clock supportive management. It is commonly used when patients experience heightened discomfort and require supportive relief in clinical settings involving chronic, unremitting symptom patterns.

Regulatory References

1. FDA Prescribing Information for AVINZA

Eligibility for AVINza Use

Use of AVINza is contraindicated for several populations, including patients with significant respiratory depression or acute or severe bronchial asthma in an unmonitored setting. It must not be used by individuals with known or suspected paralytic ileus or gastrointestinal obstruction, a documented hypersensitivity to morphine, or those who have taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Age and Condition Restrictions

The safety and efficacy have not been established for pediatric patients under 18 years of age. Older adults (aged 65 and over) are eligible but require close monitoring due to increased sensitivity. Use is conditional and requires caution for patients with severe renal or hepatic impairment due to the risk of drug accumulation. Caution is also advised for those with Chronic Pulmonary Disease or head injury. During pregnancy, use is Category C and should be administered only if clearly needed. Furthermore, the highest strength capsules (90 mg and 120 mg) are restricted for use only in patients who have established opioid tolerance.

Interactions with other medicines and products

AVINza (Morphine Sulfate Extended-Release Capsules) has specific, documented interactions that are classified by regulatory authorities as contraindicated or requiring caution.

---

Contraindicated Combinations and Time Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is prohibited, including use within 14 days of stopping MAOI treatment, due to the risk of severe reactions. The consumption of alcohol (including alcoholic beverages and medications containing alcohol) is also strictly contraindicated. In vitro data show alcohol causes a rapid release of the entire dose (dose dumping) from the extended-release capsule, which could result in potentially fatal morphine absorption.

---

Pharmacodynamic and Exposure Interactions

Interaction Type	Interacting Agents (Examples)	Official Description
Additive CNS Effects	Central Nervous System (CNS) Depressants, Muscle Relaxants, Cimetidine	Increased risk of profound sedation, respiratory depression, coma, or death.
Altered Exposure	P-Glycoprotein (PGP) Inhibitors (e.g., quinidine)	May increase systemic exposure of morphine by about two-fold via enhanced absorption.
Pharmacodynamic Risk	Anticholinergics	Increased risk of severe constipation and paralytic ileus.
Reduced Efficacy	Diuretics	Morphine may reduce the effectiveness of these agents.

---

Mixed Agonist/Antagonist Opioids (e.g., pentazocine) are advised to be avoided as they may reduce the analgesic effect or precipitate withdrawal symptoms. The labeling notes that interactions leading to respiratory depression are a heightened risk in elderly, cachectic, and debilitated patients.

AVINza is incorporated into the bone matrix following administration, where it concentrates in areas of active bone remodeling. It initiates a mechanistic cascade by selectively binding to and inhibiting the enzyme farnesyl pyrophosphate synthase (FPPS) within activated osteoclasts. This targeted molecular interaction prevents the formation of key isoprenoid lipids, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate.

This deficiency impairs the prenylation and subsequent activation of small GTPase signaling proteins, which are essential for cytoskeletal organization. Consequently, the internal cytoskeleton of the osteoclast is compromised, which limits its capacity for migration, adherence to the bone surface, and execution of bone resorption.

The resulting limitation of osteoclast activity leads to an alteration of the bone remodeling balance, characterized chemically by a reduction in circulating bone turnover markers.

How to Use AVINza

AVINza is an Extended-Release (ER) Capsule containing Morphine Sulfate, administered exclusively through the oral route. This medication is designated for once-daily use, requiring a strict 24-hour frequency to provide continuous, around-the-clock analgesic support, and is not indicated for as-needed (prn) use.

Dosing and Administration Protocol

The standard protocol for opioid-naïve patients is to initiate therapy with a 30 mg capsule taken once daily. Dose adjustments are standardized, permitting increases in increments not greater than 30 mg every 3 to 4 days. Higher strengths, such as the 90 mg and 120 mg capsules, are reserved only for patients who have already established opioid tolerance. The maximum daily dose is restricted to 1600 mg/day.

Specific Use Instructions

AVINza may be taken without regard to food. The capsule or its contents must not be chewed, crushed, dissolved, cut, or broken under any circumstances, as this would compromise the Extended-Release mechanism. If a patient is unable to swallow the capsule whole, the entire contents (beads) can be sprinkled onto a small amount of applesauce and swallowed immediately. Importantly, if a dose is missed, patients should not take the missed dose but should instead take the next scheduled dose at the usual time. High-level caution is noted for older adults (65 years and older) who may exhibit increased sensitivity to morphine.

Research Evidence / Overview of Studies for AVINza

AVINza is an extended-release formulation of morphine sulfate that was studied for the continuous, around-the-clock management of moderate to severe pain. The research base includes formal clinical trials, including placebo-controlled and active-controlled designs, as well as longer-term observational follow-up. This research provides insight into short-term changes that has been observed so far regarding its use.

---

Evidence for Use in Continuous, Around-the-Clock Pain Management

The core research consists of short-term Randomized Controlled Trials (RCTs) that research examined in adult populations experiencing chronic pain. These studies were designed to evaluate the extended-release formulation for the continuous management of symptoms. Researchers focused on outcomes related to physical discomfort, often using scales to measure pain intensity scores over the study period. Trials also monitored how often patients needed to use immediate-release rescue medication for temporary flare-ups of discomfort. These findings describe patterns observed in the studies over the short-term trial duration.

Evidence in Chronic Non-Cancer Pain (CNCP)

The extended-release formulation was evaluated in studies involving adults with conditions marked by functional limitations, such as chronic low back pain or osteoarthritis. The evidence is limited regarding the measurement of patient-reported outcomes describing perceived discomfort when observed over periods longer than a few months.

Evidence in Pain Associated with Malignancy (Cancer Pain)

Research for this use often involves comparative studies where the extended-release capsule was observed in adult patients with cancer-related pain. Since the underlying active ingredient (morphine) is a well-established compound, these studies were designed to explore whether the extended-release format showed similar measurements to standard immediate-release morphine solutions when used for maintenance therapy. The studies primarily examined pain intensity scores and the rates of breakthrough pain.

---

Long-Term Studies and Follow-Up Data

Most formal, highly controlled trials had follow-up durations that were limited, typically lasting only a few weeks to a few months. To gather information on sustained use, researchers conducted open-label extension studies and observational settings evaluating daily-life functioning where patients were followed for longer periods. However, because these longer-term studies were not blinded or placebo-controlled, the certainty remains low when drawing conclusions about functional outcomes or quality of life measurements over extended periods. There is limited information for long-term outcomes that is derived from the highest quality of research.

---

What is Still Uncertain About the Research Base

The research base has several known limitations. The follow-up durations were limited in the most rigorous, controlled clinical trials, meaning that long-term effects are not fully established based on that highest tier of evidence. Additionally, the sample sizes were modest in some of the initial trials. The results apply only to the populations studied, and the research does not determine whether an individual will respond similarly, highlighting that the evidence is a description of group patterns under specific conditions.

Key Studies & References

1. FDA Prescribing Information for AVINZA (Morphine Sulfate Extended-Release Capsules)
2. NIH DailyMed (General Drug Information on Morphine Sulfate)

Common questions about AVINza (FAQ)

Q: What is the main ingredient in AVINza?

The main active ingredient in AVINza is morphine sulfate. This substance is an opioid medicine used for the management of chronic, moderate-to-severe pain. The official product information confirms that morphine sulfate is the compound responsible for the medicine's pain-relieving effects.

Q: How long does the pain relief from AVINza last?

AVINza is an extended-release medicine, formulated to release the active ingredient over a longer period of time. Official documents state that this medicine is designed to provide consistent pain relief for up to 24 hours. This formulation is designed to support once-daily administration, as specified in the official dosing guidelines.

Q: Can I take AVINza with food?

According to the official product information, AVINza can be taken with food. However, regulatory documents state that it should not be taken with alcohol. The official documentation provides this information to support the proper administration and function of the medication.

Q: What should I do if I miss a dose of AVINza?

Regulatory documents state that if a dose of AVINza is missed, the next dose should be taken at the next regularly scheduled time. The instructions advise against taking a double dose to compensate for a missed one. Specific guidance on missed doses is detailed within the official regulatory product information.

Q: Can AVINza be used for pain after surgery?

The official product information specifies that AVINza is intended for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. It is generally not indicated for 'as needed' use for short-term pain, such as the pain immediately following a surgery. The medicine's use is focused on chronic pain.

How to Store and Dispose of AVINza?

This section outlines the official regulatory requirements for storing and disposing of AVINza (Morphine Sulfate Extended-Release Capsules).

Storage and Handling Requirements

• Mandatory Storage: Store the medication at controlled room temperature, away from heat, moisture, and light to maintain stability.
• Security: As a Schedule II controlled substance, AVINza must be stored securely to prevent theft, misuse, and unauthorized access.
• Handling Constraint: The capsules must be swallowed intact (whole). Do not crush, chew, or dissolve the capsules or their contents, as this action releases the medicine too quickly and can result in the rapid absorption of a potentially fatal dose.
• Child Safety: Keep the medicine out of sight and reach of children.

Official Disposal Rules

Due to the risks of misuse and fatal overdose, unused capsules require secure and timely disposal.

• Preferred Method: Patients are advised to use a drug take-back disposal program available through pharmacies or community programs.
• Alternative Method: If a take-back program is not immediately available, patients should flush unused capsules down the toilet as permitted for this controlled substance to prevent diversion and accidental ingestion.